Clinical trial
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.
NCT00961090 is registered in ClinicalTrials.gov with Matthew R Quigley as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.
- Lead sponsor
- Matthew R Quigley
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2009
- Completion date
- April 23, 2015
- Enrollment
- 72 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.